The use of animal models for cancer chemoprevention drug development

Seminars in Oncology

Volumn 37, Issue 4, 2010, Pages 327-338

  Steele, Vernon E ^a   Lubet, Ronald A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ANTITUMOR B; AROMATASE INHIBITOR; ATORVASTATIN; BIOLOGICAL MARKER; CATECHIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ERLOTINIB; FENRETINIDE; FLUOROURACIL; GEFITINIB; GLUCOCORTICOID; HERBACEOUS AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ORNITHINE DECARBOXYLASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RESVERATROL; TAMOXIFEN; UAB 30; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOMATOUS POLYP; BLADDER CANCER; BREAST CANCER; BREAST TUMOR; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON ADENOMA; COLON CANCER; COLORECTAL CANCER; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; ESOPHAGUS CANCER; GENE DELETION; GENE INSERTION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKIN CANCER; TRANSGENIC ANIMAL; TUMOR MODEL; ANIMAL; DRUG DESIGN; DRUG SCREENING; NEOPLASMS;

ANIMALS; ANTICARCINOGENIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956371555     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.05.010     Document Type: Article

References (84)

1. R.C. Moon, and R.G. Mehta Chemoprevention of experimental carcinogenesis in animals Prev Med 18 1989 576 591
2. J. Russo, X. Yang, and Y.F. Hu Biological and molecular basis of human breast cancer Front Biosci 3 1998 D944 D960
3. R.A. Lubet, V.E. Steele, and R. DeCoster Chemopreventive effects of the aromatase inhibitor vorozole (R83842) in the methylnitrosourea-induced mammary cancer model Carcinogenesis 19 1998 1345 1351
4. R.A. Lubet, V.E. Steele, and T.L. Casebolt Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU) - induced mammary tumor model in Sprague-Dawley rats Carcinogenesis 15 1994 2775 2780
5. K. Christov, A. Shilkaitis, and A. Green Cellular responses of mammary carcinomas to aromatase inhibitors: effects of vorozole Breast Cancer Res Treat 60 2000 117 128
6. M. Baum, A. Buzdar, J. Cuzick ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810
7. R.C. Moon, G.J. Kelloff, and C.J. Detrisac Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen Anticancer Res 12 1992 1147 1153
8. D.L. McCormick, R.G. Mehta, and C.A. Thompson Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl) retinamide and ovarectomy Cancer Res 42 1982 508 512
9. R.C. Moon, V.E. Steele, and G.J. Kelloff Chemoprevention of MNU-induced mammary tumorigenesis by hormone modifying agents: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone Anticancer Res 14 1994 889 894
10. R.C. Moon, C.J. Grubbs, and M.B. Sporn Inhibition of 7,12-dimethylbenz(a) anthracene-induced mammary carcinogenesis by retinyl acetate Cancer Res 36 1976 2626 2630
11. C.J. Grubbs, V.E. Steele, and T. Casebolt Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol Anticancer Res 15 1995 709 716
12. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
13. X. Xu, K.-U. Wagner, and D. Larson Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation Nat Genet 22 1999 37 43
14. S. Rottenberg, J.E. Jaspers, and A. Kersbergen High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci U S A 105 2008 17079 17084
15. J.E. Green, M.A. Shibata, and E. Shibata 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice Cancer Res 61 2001 7449 7455
16. J.I. Herschkowitz, K. Simin, and V.J. Weigman Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors Genome Biol 8 2007 R76
17. R.A. Lubet, D. Boring, and V.E. Steele Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis Cancer Prev Res 2 2009 161 167
18. C.J. Grubbs, R.A. Lubet, and V.R. Atigadda Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers Carcinogenesis 27 2006 1232 1239
19. R.A. Lubet, K. Christov, and M. You Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations Mol Cancer Ther 5 2006 1073 1078
20. R.A. Lubet, K. Christov, and N.P. Nunez Efficacy of targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis Carcinogenesis 26 2005 441 448
21. R.L. Jones, J. Salter, and R. A'Hern The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 2009
22. L.W. Wattenberg, T.S. Wiedmann, and R.D. Estensen Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice Cancer Res 57 1997 5489 5492
23. L.W. Wattenberg, T.S. Wiedmann, and R.D. Estensen Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol Carcinogenesis 21 2000 179 182
24. R. Yao, Y. Wang, and W.J. Lemon Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions Oncogene 23 2004 7746 7752
25. Z. Zhang, Y. Wang, and R. Yao Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models Oncogene 23 2004 3841 3850
26. Z. Zhang, Y. Wang, and L.E. Lantry Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf Oncogene 22 2003 6257 6265
27. R.C. Moon, K.V. Rao, and C.J. Detreisac Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination Int J Oncol 4 1994 661 667
28. L.W. Wattenberg, T.S. Wiedmann, and R.D. Estensen Chemoprevention of cancer of the upper respiratory tract of the Syrian Golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil Cancer Res 64 2004 2347 2349
29. Y. Wang, Z. Zhang, and Y. Yan A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility Cancer Res 64 2004 1647 1654
30. S.S. Hecht, C.B. Chen, and T. Ohmori Comparative carcinogenicity in F344 rats of the tobacco-specific nitrosamines, N′-nitrosonornicotine and 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone Cancer Res 40 1980 298 302
31. A. Castonguay, P. Pepin, and G.D. Stoner Lung tumorigenicity of NNK given orally to A/J mice: its application to chemopreventive efficacy studies Exp Lung Res 17 1991 485 499
32. C.C. Conway, D. Jiao, and G.J. Kelloff Chemopreventive potential of fumaric acid, N-acetyl-l-cysteine, N-(4-hydroxyphenyl) retinamide, and β-carotene for tobacco nitrosamine induced lung tumors in A/J mice Cancer Lett 24 1998 85 93
33. W.T. Gunning, P.M. Kramer, and R.A. Lubet Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice Exp Lung Res 26 2000 757 772
34. R. Balansky, G. Ganchev, and M. Iltcheva Potent carcinogenicity of cigarette smoke in mice exposed early in life Carcinogenesis 28 2007 2236 2243
35. R. Balansky, G. Ganchev, and M. Iltcheva Prevention of cigarette smoke-induced lung tumors in mice by budesonide, phenethyl isothiocyanate, and N-acetylcysteine Int J Cancer 126 2010 1047 1054
36. J. Calb, R. Meuwissen, and E. van Montfort Genotype-phenotype relationships in a mouse model for human small-cell lung cancer Cold Spring Harb Symp Quant Biol 70 2005 225 232
37. C.V. Rao, B.S. Reddy, and V.E. Steele Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets Mol Cancer Ther 5 2006 1530 1538
38. B.S. Reddy, C.X. Wang, and A.N. Kong Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats Cancer Res 66 2006 4542 4546
39. J. Raju, M.V. Swamy, and I. Cooma Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence Int J Cancer 113 2005 798 802
40. V.E. Steele, C.W. Boone, and D. Dauzonne Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon Cancer Res 62 2002 6506 6509
41. R.F. Jacoby, K. Seibert, and C.E. Cole The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis Cancer Res 60 2000 5040 5044
42. B.S. Reddy, T. Kawamori, and R.A. Lubet Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process Cancer Res 59 1999 3387 3391
43. M.M. Bertagnolli, C.J. Eagle, and A.G. Zauber celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 874 884
44. N. Arber, C. Eagle, and J. Spicak Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895
45. H. Li, H.A.J. Schut, and P. Conran Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon Carcinogenesis 20 1999 425 430
46. P.H. Gann, J.E. Manson, and R.J. Glynn Low-dose aspirin and incidence of colorectal tumors in a randomized trial J Natl Cancer Inst 85 1993 1220 1224
47. N.R. Cook, I.-M. Lee, and J.M. Gaziano Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial JAMA 294 2005 47 55
48. V.E. Steele, C.J. Grubbs, and C.V. Rao Chemopreventive efficacy of naproxen and NO-naproxen in rodent models of colon and urinary bladder, and mammary cancer Cancer Prev Res 2 2009 951 956
49. R.F. Jacoby, C.E. Cole, and E.T. Hawk Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis Gastroenterology 127 2004 838 844
50. J.L. Williams, K. Kashfi, and N. Ouyang NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice Biochem Biophys Res Commun 313 2004 784 788
51. M.V. Swamy, J.M. Patlolla, and V.E. Steele Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice Cancer Res 66 2006 7370 7377
52. C.J. Grubbs, R.A. Lubet, and A.T. Koki Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancer in male B6D2F1 mice and female F344 rats Cancer Res 60 2000 5599 5602
53. R. Yao, W.J. Lemon, and Y. Wang Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine Neoplasia 6 2004 569 577
54. R.A. Lubet, K. Huebner, and L.Y. Fong 4-Hydroxybutyl(butyl)nitrosamine- induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin Carcinogenesis 26 2005 571 578
55. M.C. Bosland, M.K. Prinsen, and R. Kroes Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone Cancer Lett 18 1983 69 78
56. D.L. McCormick, W.D. Johnson, and T.M. Haryu Null effect of dietary restriction on prostate carcinogenesis in the Wistar-Unilever rat Nutr Cancer 57 2007 194 200
57. D.L. McCormick, W.D. Johnson, and N.M. Kozub Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis 28 2007 398 403
58. J.E. Green, M.A. Shibata, and E. Shibata 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice Cancer Res 61 2001 7449 7455
59. X. Ma, A.C. Ziel-van der Made, and B. Autar Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis Cancer Res 65 2005 5730 5739
60. D.L. McCormick, and R.C. Moon Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice Cancer Lett 31 1986 133 138
61. B.S. Warren, and T.J. Slaga Mechanisms of inhibition of tumor progression Basic Life Sci 61 1993 279 289
62. J. DiGiovanni Multistage carcinogenesis in mouse skin Pharmacol Ther 54 1992 63 128
63. W.E. Poel Effect of carcinogen dosage and duration of exposure on skin-tumor induction in mice J Natl Cancer Inst 22 1959 19 43
64. K.E. Burke, J. Clive, and G.F. Combs Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice Nutr Cancer 38 2000 87 97
65. S.M. Fischer, H.H. Lo, and G.B. Gordon Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis Mol Carcinog 25 1999 231 240
66. Y.P. Lu, Y.R. Lou, and Y. Lin Inhibitory effects of orally administered green tea, black tea, and caffeine on skin carcinogenesis in mice previously treated with ultraviolet B light (high-risk mice): relationship to decreased tissue fat Cancer Res 61 2001 5002 5009
67. S.M. Fischer, C.J. Conti, and J. Viner Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis 24 2003 945 952
68. S.M. Fischer, M. Lee, and R.A. Lubet Difluoromethylornithine is effective as both a preventive and therapeutic agent against the development of UV carcinogenesis in SKH hairless mice Carcinogenesis 22 2001 83 88
69. M. Athar, X. Tang, and J.L. Lee Hedgehog signaling in skin development and cancer Exp Dermatol 15 2006 667 677
70. P.L. So, K. Lee, and J. Hebert Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation Cancer Res 64 2004 4385 4389
71. K.A. Crist, Z. Zhang, and M. You Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture Carcinogenesis 26 2005 951 957
72. D. Xing, and S. Orsulic A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma Cancer Res 66 2006 8949 8953
73. A.A. Hakim, C.P. Barry, and H.J. Barnes Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu Cancer Prev Res 2 2009 114 121
74. A. Wax, J.W. Pyhtila, and R.N. Graf Prospective grading of neoplastic change in rat esophagus using angle-resolve low coherance interferometry J Biomed Optics 10 2005 0516040110
75. X. Chen, S. Wang, and N. Wu Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis Clin Cancer Res 10 2004 6703 6709
76. X. Chen, N. Li, and S. Wang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis 23 2002 2095 2102
77. T.L. Vaughan, L.M. Dong, and P.L. Blount Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol 6 2005 945 952
78. O.G. Opitz, H. Harada, and Y. Suliman A mouse model of human oral-esophageal cancer J. Clin Invest 110 2002 761 769
79. M. Ohne, K. Omori, and A. Kobayashi Induction of squamous cell carcinoma in the oral cavity of rats by oral administration of 4-nitroquinoline-1-oxide (4NQO) in drinking water A preliminary report Bull Tokyo Dent Coll 22 1981 85 98
80. M. Ohne, T. Satoh, and S. Yamada Experimental tongue carcinoma of rats induced by oral administration of 4-nitroquinoline 1-oxide (4NQO) in drinking water Oral Surg Oral Med Oral Pathol 59 1985 600 607
81. S.J. Gerson Oral cancer Crit Rev Oral Biol Med 1 1990 153 166
82. D.L. McCormick, J.M. Phillips, and T.L. Horn Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and non-selective COX Inhibitors Cancer Prev Res 3 2010 73 81
83. N. Ouyang, J.L. Williams, and G.J. Tsioulias Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model Cancer Res 66 2006 4503 4511
84. L.S. Freedman, D.C. Midthune, and C.C. Brown : Statistical analysis of animal cancer chemoprevention experiments Biometrics 49 1993 259 268